Lyka Labs Ltd

Lyka Labs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, recorded a fresh 52-week low of Rs.51.17 on 17 Mar 2026, marking a significant decline amid persistent underperformance and deteriorating financial metrics.

Lyka Labs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.51.45 today, marking a significant decline in its stock price amid ongoing financial and market pressures. This fresh low underscores the stock’s persistent underperformance relative to its sector and benchmark indices.

Lyka Labs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.54 today, marking a significant decline amid ongoing market pressures and company-specific headwinds. The stock has underperformed its sector and benchmark indices, reflecting persistent challenges in its financial and technical performance.

Lyka Labs Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 12 January 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock’s current position as of 12 March 2026, providing investors with the latest comprehensive analysis.

Lyka Labs Ltd’s shares declined to a fresh 52-week low of Rs.55 on 11 Mar 2026, marking a significant milestone in the stock’s ongoing downward trajectory. This new low reflects persistent pressures on the company’s valuation amid subdued financial performance and broader market headwinds.

Lyka Labs Ltd’s share price declined to a fresh 52-week low of Rs.56 on 10 Mar 2026, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical and biotechnology company’s shares have been under pressure, reflecting a series of financial and market challenges that have weighed on investor sentiment.

Lyka Labs Ltd’s share price has declined to a fresh 52-week low, closing just 0.7% above its lowest level of Rs 56.6. The stock’s recent performance reflects ongoing pressures within the Pharmaceuticals & Biotechnology sector, with the company’s shares underperforming both the sector and broader market indices.

Lyka Labs Ltd has reached a 52-week low, with its share price touching Rs 60.59 on 2 Mar 2026, marking a significant decline amid ongoing pressures in the Pharmaceuticals & Biotechnology sector. The stock’s recent performance reflects a continuation of a downward trend, with multiple factors contributing to its current valuation.

Lyka Labs Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 12 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 27 February 2026, providing investors with the latest insights into the company’s performance and outlook.

Lyka Labs Ltd, a player in the Pharmaceuticals & Biotechnology sector, recorded a new 52-week low of Rs.56.6 today, marking a significant decline in its stock price amid ongoing financial and market pressures. Despite a modest intraday recovery, the stock remains below all key moving averages, reflecting persistent challenges in its performance over the past year.

Lyka Labs Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.60 today, marking a significant decline in its stock price amid ongoing challenges. This latest low comes after a sustained period of underperformance relative to the broader market and sector benchmarks.

Lyka Labs Ltd, a player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of Rs.61.03, marking a significant decline amid a sustained downtrend. The stock has underperformed its sector and benchmark indices, reflecting ongoing financial pressures and subdued market sentiment.

Lyka Labs Ltd, a player in the Pharmaceuticals & Biotechnology sector, recorded a new 52-week low of Rs.65 today, marking a significant decline in its share price amidst ongoing market pressures and company-specific challenges.

Lyka Labs Ltd’s share price declined to a fresh 52-week low of Rs.66.33 today, marking a significant milestone in its ongoing downward trajectory. The stock has underperformed its sector and benchmark indices, reflecting persistent pressures on the company’s financial and market performance.

Lyka Labs Ltd’s shares declined to a fresh 52-week low of Rs.66.75 on 16 Feb 2026, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical company’s stock has underperformed its sector and benchmark indices, reflecting persistent headwinds and subdued financial performance over the past year.

Lyka Labs Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 12 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 16 February 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.

Lyka Labs Ltd, a player in the Pharmaceuticals & Biotechnology sector, has witnessed its stock price decline to a fresh 52-week low of Rs.68.08 on 13 Feb 2026, marking a significant downturn amid broader market fluctuations and company-specific pressures.

Lyka Labs Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 12 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 February 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market standing.

Lyka Labs Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.70 today, marking a significant decline in its stock price amid ongoing market pressures and company-specific challenges.